Juvenile myoclonic epilepsy: Long-term prognosis and risk factors

• Published in: Brain & development (Tokyo. 1979) 2021-06, Vol.43 (6), p.688-697
• Main Authors: Pietrafusa, Nicola, La Neve, Angela, de Palma, Luca, Boero, Giovanni, Luisi, Concetta, Vigevano, Federico, Specchio, Nicola
• Format: Article
• Language: English
• Subjects: Antiseizure medications; Juvenile myoclonic epilepsy; Long-term outcome; Prognosis
• ISSN: 0387-7604; 1872-7131
• DOI: 10.1016/j.braindev.2021.02.005

Our goal was to investigate the long-term clinical course of juvenile myoclonic epilepsy (JME) in a cohort of patients and to identify prognostic factors for refractoriness and seizure relapse after anti-seizure medications (ASMs) withdrawal. A literature review is also presented to consolidate and compare our findings with the previously reported cases. We retrospectively studied a series of patients diagnosed with JME with 15 years or more of evolution. We collected clinical, neurophysiological and neuroimaging data from patients who met defined inclusion and exclusion criteria. Study involved 61 patients (65.5% female) with mean age at study of 37.6 years, and mean age at its outset of 14.8 years. Median follow-up was 31.0 years (mean 28.9, range 15–53). They presented more frequently with a combination of myoclonic and generalized tonic-clonic seizures (GTCS) (65.6%). Sixty-five percent of patients (n = 40) had a 5-year terminal remission with a mean age at last seizure of 27.4 years. Thirty-two percent of seizure-free patients (n = 13) withdrew ASMs: 6 out of 13 had a recurrence of the seizures while 7 remained seizure-free (mean age at ASMs withdrawal 21.0 versus 35.7 years, p